Disease · MONDO_0007275

carpal tunnel syndrome

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. carpal tunnel syndrome. Diseases, record MONDO_0007275. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0007275

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: carpal tunnel syndrome; Open Targets
Open Targets ID: MONDO_0007275; Open Targets
Disease Ontology: DOID:12169; Disease Ontology
MeSH: D002349; MeSH
NCI Thesaurus: C34450; NCI Thesaurus
Orphanet: ORPHA:50838; Orphanet
Highest stage of its drugs: Phase 3, for 14 of its 41 drugs, from ClinicalTrials.gov; Open Targets

Drugs41

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
LIDOCAINE	CHEMBL79	Small molecule	Phase 3	ClinicalTrials.gov	10	10	10	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Phase 3	ClinicalTrials.gov	8	8	3	Drugs and targets
DEXTROSE	CHEMBL1222250	Small molecule	Phase 3	ClinicalTrials.gov	8	8	8	Drugs and targets
METHYLPREDNISOLONE	CHEMBL650	Small molecule	Phase 3	ClinicalTrials.gov	8	8	3	Drugs and targets
BETAMETHASONE	CHEMBL632	Small molecule	Phase 3	ClinicalTrials.gov	7	7	2	Drugs and targets
TRIAMCINOLONE	CHEMBL1451	Small molecule	Phase 3	ClinicalTrials.gov	7	7	2	Drugs and targets
BETAMETHASONE SODIUM PHOSPHATE	CHEMBL1200762	Small molecule	Phase 3	ClinicalTrials.gov	6	6	1	Drugs and targets
METHYLPREDNISOLONE ACETATE	CHEMBL1364144	Small molecule	Phase 3	ClinicalTrials.gov	6	6	2	Drugs and targets
PREDNISOLONE	CHEMBL131	Small molecule	Phase 3	ClinicalTrials.gov	6	6	1	Drugs and targets
BETAMETHASONE DIPROPIONATE	CHEMBL1200384	Small molecule	Phase 3	ClinicalTrials.gov	5	5	2	Drugs and targets

1 to 10 of 41

See all 41 drugs

Targets107

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	12	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
SCN4A	Sodium channel alpha subunit	7	Sodium channel alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6329	Drugs and targets
SCN10A	Sodium channel alpha subunit	6	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6336	Drugs and targets
SCN11A	Sodium channel alpha subunit	6	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/11280	Drugs and targets
SCN1A	Sodium channel alpha subunit	6	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6323	Drugs and targets
SCN2A	Sodium channel alpha subunit	6	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6326	Drugs and targets
SCN3A	Sodium channel alpha subunit	6	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6328	Drugs and targets
SCN5A	Sodium channel alpha subunit	6	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6331	Drugs and targets
SCN7A	Sodium channel alpha subunit	6	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6332	Drugs and targets
SCN8A	Sodium channel alpha subunit	6	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6334	Drugs and targets

1 to 10 of 107

See all 107 targets

Trials56

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 5 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04833777	Does a Different Local Anesthetic Improve Pain After Carpal Tunnel Release?	Not applicable	140	2025-02-10	Carpal Tunnel Syndrome	BUPIVACAINE, LIDOCAINE	Its record names the disease	ClinicalTrials.gov
NCT05416515	A Study of Fisetin to Treat Carpal Tunnel Syndrome	Phase 2	40	2025-12-24	Carpal Tunnel Syndrome	FISETIN	Its record names the disease	ClinicalTrials.gov
NCT02070302	BOTOX® (Onabotulinumtoxin A) Injection(s) as a Treatment for Carpal Tunnel Syndrome	Phase 2	10	2017-09-27	Carpal Tunnel Syndrome	ONABOTULINUMTOXINA	Its record names the disease	ClinicalTrials.gov
NCT04781777	Effect of Ultrasonographic Guided Insulin Injection With Dexamethasone and Local Anesthetic Mixture in Diabetic Patients With Mild to Moderate Carpal Tunnel .	Not applicable	250		Pain Relief	INSULIN HUMAN	Its record names the disease	ClinicalTrials.gov
NCT07042282	Comparison of Initial Treatment for Carpal Tunnel Syndrome Related to Rheumatic Diseases: Corticosteroid Injection Versus Nighttime Splinting	Not applicable	248		Carpal Tunnel Syndrome (CTS), Rheumatic Diseases	METHYLPREDNISOLONE	Its record names the disease	ClinicalTrials.gov
NCT00029497	Sham Device, Pill Placebo or Treatment For Arm Pain	Phase 2	240		Cumulative Trauma Disorders, Repetitive Strain Injury, Carpal Tunnel Syndrome, Pain	AMITRIPTYLINE	Its record names the disease	ClinicalTrials.gov
NCT00266214	Safety and Efficacy of Lidoderm (Lidocaine Patch 5%) in Treating Moderate to Severe Pain Associated With Carpal Tunnel Syndrome	Phase 3	210		Carpal Tunnel Syndrome	LIDOCAINE	Its record names the disease	ClinicalTrials.gov
NCT05411900	BotulInum Toxin Type A for Peripheral Neuropathic Pain in subjEcts With Carpal Tunnel Syndrome	Phase 2	164		Carpal Tunnel Syndrome, Neurogenic Inflammation, Pain, Drug Use, Neuropathic Pain	BOTULINUM TOXIN TYPE A	Its record names the disease	ClinicalTrials.gov
NCT00137735	Gabapentin for Carpal Tunnel Syndrome	Phase 3	150		Carpal Tunnel Syndrome	GABAPENTIN	Its record names the disease	ClinicalTrials.gov
NCT06133712	Dexmedetomidine, Ozone and Dexamethasone Local Injection in Carpal Tunnel Syndrome for Pain Relief	Not applicable	135		Carpal Tunnel, Dexmedetomidine, Ozone, Dexamethasone	DEXAMETHASONE, DEXMEDETOMIDINE, OZONE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 56

See all 56 trials

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Lidocaine vs Bupivacaine: deaths from any cause	0 of 67	0 of 72	139	NCT04833777	Trial comparisons
Lidocaine vs Bupivacaine: serious adverse events	0 of 67	0 of 72	139	NCT04833777	Trial comparisons
Botulinum Toxin Type A vs Placebo: deaths from any cause	0 of 5	0 of 5	10	NCT02070302	Trial comparisons
Botulinum Toxin Type A vs Placebo: serious adverse events	0 of 5	0 of 5	10	NCT02070302	Trial comparisons

Papers from its trials50

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41233154	RESULT	1	PubMed
40272357	RESULT	1	PubMed
37031817	RESULT	1	PubMed
30339737	RESULT	2	PubMed
30187524	RESULT	1	PubMed
28778254	RESULT	2	PubMed
28622409	RESULT	1	PubMed
28375915	RESULT	1	PubMed
28205574	RESULT	1	PubMed
27751557	RESULT	1	PubMed

1 to 10 of 50

See all 50 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0007275

GET https://conductscience.org/api/diseases/v1/MONDO_0007275/drugs?page=2

API reference For AI assistants